Protamine
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
BOXED WARNING
See full prescribing information for complete Boxed Warning.
* Protamine sulfate can cause severe hypotension, cardiovascular collapse, noncardiogenic pulmonary edema, catastrophic pulmonary vasoconstriction, and pulmonary hypertension. Risk factors include high dose or overdose, rapid administration, repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). Allergy to fish, previous vasectomy, and severe left ventricular dysfunction and abnormal preoperative pulmonary hemodynamics also may be risk factors. In patients with any of these risk factors, the risk to benefit of administration of protamine sulfate should be carefully considered. Vasopressors and resuscitation equipment should be immediately available in case of a severe reaction to protamine. Protamine sulfate should not be given when bleeding occurs without prior heparin use.
|
Overview
Protamine is a heparin antagonist that is FDA approved for the {{{indicationType}}} of heparin overdosage. There is a Black Box Warning for this drug as shown here. Common adverse reactions include flushing, dyspnea, nausea, and vomiting.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Heparin Overdosage
- Dosing Information
- Each mg of protamine sulfate, calculated on the dried basis, neutralizes not less than 100 USP Heparin Units.
- Protamine sulfate injection should be given by very slow intravenous injection over a 10-minute period in doses not to exceed 50 mg.
- Protamine sulfate is intended for injection without further dilution; however, if further dilution is desired, D5-W or normal saline may be used. Diluted solutions should not be stored since they contain no preservative.
- Protamine sulfate should not be mixed with other drugs without knowledge of their compatibility, because protamine sulfate has been shown to be incompatible with certain antibiotics, including several of the cephalosporins and penicillins.
- Because heparin disappears rapidly from the circulation, the dose of protamine sulfate required also decreases rapidly with the time elapsed following intravenous injection of heparin. For example, if the protamine sulfate is administered 30 minutes after the heparin, one-half the usual dose may be sufficient.
- The dosage of protamine sulfate should be guided by blood coagulation studies.
- Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration, whenever solution and container permit.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Protamine in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Protamine in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
- Safety and effectiveness in children have not been established.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Protamine in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Protamine in pediatric patients.
Contraindications
- Condition1
Warnings
BOXED WARNING
See full prescribing information for complete Boxed Warning.
* Protamine sulfate can cause severe hypotension, cardiovascular collapse, noncardiogenic pulmonary edema, catastrophic pulmonary vasoconstriction, and pulmonary hypertension. Risk factors include high dose or overdose, rapid administration, repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). Allergy to fish, previous vasectomy, and severe left ventricular dysfunction and abnormal preoperative pulmonary hemodynamics also may be risk factors. In patients with any of these risk factors, the risk to benefit of administration of protamine sulfate should be carefully considered. Vasopressors and resuscitation equipment should be immediately available in case of a severe reaction to protamine. Protamine sulfate should not be given when bleeding occurs without prior heparin use.
|
- Description
Precautions
- Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Protamine in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Protamine in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Drug Interactions
- Drug
- Description
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Protamine in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Protamine during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Protamine with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Protamine with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Protamine with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Protamine with respect to specific gender populations.
Race
There is no FDA guidance on the use of Protamine with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Protamine in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Protamine in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Protamine in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Protamine in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
- Intravenous
Monitoring
There is limited information regarding Monitoring of Protamine in the drug label.
Condition1
- Description
IV Compatibility
There is limited information regarding IV Compatibility of Protamine in the drug label.
Overdosage
Acute Overdose
Signs and Symptoms
- Description
Management
- Description
Chronic Overdose
There is limited information regarding Chronic Overdose of Protamine in the drug label.
Pharmacology
There is limited information regarding Protamine Pharmacology in the drug label.
Mechanism of Action
Structure
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Protamine in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Protamine in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Protamine in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Protamine in the drug label.
Condition1
- Description
How Supplied
- Protamine Sulfate Injection, USP, 50 mg (10 mg/mL, 5 mL) in a single dose flip-top vial, in packages of 25.
- Protamine Sulfate Injection, USP, 250 mg (10 mg/mL, 25 mL) in a single dose flip-top vial, packaged individually.
- Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not permit to freeze.
- CAUTION: The total dose of protamine sulfate contained in product No. 22930 (250 mg in 25 mL) is 5 times greater than in product No. 22905 (50 mg in 5 mL).
- The large size 25 mL vials are designed for antiheparin treatment only when large doses of heparin have been given during surgery and are to be neutralized by large doses of protamine sulfate after surgical procedures.
Storage
There is limited information regarding Protamine Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Protamine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Protamine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Protamine in the drug label.
Precautions with Alcohol
- Alcohol-Protamine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- Protamine sulfate®[1]
Look-Alike Drug Names
- protamine — Protonix®[2]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ "PROTAMINE SULFATE injection, solution".
- ↑ "http://www.ismp.org". External link in
|title=
(help)
{{#subobject:
|Page Name=Protamine |Pill Name=No image.jpg |Drug Name= |Pill Ingred=|+sep=; |Pill Imprint= |Pill Dosage= |Pill Color=|+sep=; |Pill Shape= |Pill Size (mm)= |Pill Scoring= |Pill Image= |Drug Author= |NDC=
}}
{{#subobject:
|Label Page=Protamine |Label Name=Protamine02.png
}}
{{#subobject:
|Label Page=Protamine |Label Name=Protamine03.png
}}